Psychiatry News

BOSTON — Girls and boys who experienced stress early in life were more likely than those with lower stress scores to use alcohol, nicotine and cannabis by age 13 years, according to a presenter at ENDO 2024.

NEW YORK — Factors across multiple domains, including demographic characteristics and parenting behaviors, appeared predictive of substance use initiation in early adolescence, according to study results.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

Preteens whose parents were incarcerated or arrested were more likely to experience suicidal ideation, according to research published in Pediatrics.

Insufficient sleep was tied to poorer cognition and attention in adolescents who were classified as having overweight or obesity based on their BMI compared with those with normal weight, according to a recent study in JAMA Neurology.

Women diagnosed with preeclampsia were 2.6 times more likely to develop early-onset dementia during 9 years of follow-up compared with women who did not have a hypertensive disorder of pregnancy, according to registry data.

The National Alliance on Mental Illness (NAMI) estimates that one in five U.S. adults are currently living with mental health issues. In acknowledgement and celebration of Mental Health Awareness Month, NAMI has launched the “Take the Moment” campaign, encouraging individuals to build community connection, hold conversations and act now by using available resources.

Teenagers who use cannabis have a much higher risk for developing a psychotic disorder compared with their nonusing peers, according to research published in Psychological Medicine.

Sleep issues, self-harm and high levels of social media and smartphone use were prevalent among young people with mental health conditions, according to research published in PLoS One.

Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.